Ilaria Marech

Author PubWeight™ 6.44^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Dasatinib: an anti-tumour agent via Src inhibition.	Curr Drug Targets	2011	1.15
2	TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer?	J Clin Oncol	2012	1.07
3	Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.	Clin Exp Med	2013	1.01
4	Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients: possible translational significance.	BMC Cancer	2014	0.87
5	Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.	J Pathol	2012	0.84
6	Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.	Crit Rev Oncol Hematol	2013	0.80
7	Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients.	Curr Drug Metab	2011	0.77
8	Novel plant-derived target drugs: a step forward from licorice?	Expert Opin Ther Targets	2013	0.77
9	Complete response to second line Paclitaxel every 2 weeks of eyelid kaposi sarcoma: a case report.	Ophthal Plast Reconstr Surg	2013	0.75
10	Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.	Tumori	2013	0.75